Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Research Council grant · Running

RESET-DMG Decoding the transcriptional and evolutionary maps of diffuse midline glioma to overcome treatment resistance

Coordinator
Uppsala Universitet, Sweden
Runs
1 December 2026 to 30 November 2031
Status
Running
EU funding
€1.4m
Total cost
€1.4m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101300870

What the project is doing

In the project's own words, from its summary on CORDIS.

In Europe, cancer is the leading cause of disease-related deaths in children. Among these, the pediatric brain tumor diffuse midline glioma (DMG) is the most lethal, with a median survival of only 9–11 months. Surgical resection is not possible due to its location, and radiation –the current standard of care– provides only temporary benefit before resistance develops. A hallmark of DMG is loss of the H3K27me3 epigenetic repressive mark, which stalls cancer cells into proliferative, stem-like states driven by transcription factor (TF) dysregulation.

My research indicates that these TF-mediated programs not only sustain tumor growth but also influence treatment response, suggesting they represent actionable targets to both impair tumor progression and enhance the efficacy of targeted therapies. RESET-DMG will investigate how TF-mediated transcriptional states cooperate with genetic alterations to drive treatment resistance in DMG. Aim 1 will establish proof-of-concept that disrupting these transcriptional states enhances the efficacy of TP53 reactivation– a therapeutic strategy with particular promise for the >40% of DMGs retaining wild-type TP53.

This will be evaluated in patient-derived neurospheres, brain organoids, and orthotopic mouse xenograft models. Aim 2 will expand this question to eight clinically-relevant targeted therapies in DMG, generating resistant cell line models and profiling emerging cell populations with single-cell barcoding and multiome technologies across treatment modalities. Aim 3 will use predictive modelling to identify the features that contribute the most to treatment resistance in our generated cell line models, validating them in vitro and in a cohort of >70 human DMG samples, with the goal of informing therapeutic strategies for primary and relapsed disease.

Upon completion, I envision this interdisciplinary project will establish a framework for rational therapeutic combinations designed to overcome treatment resistance in DMG.

Topics

Who is involved

OrganisationCityCountryRole
Uppsala UniversitetUppsalaSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI